171 related articles for article (PubMed ID: 18768867)
1. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions.
Baudino L; Nimmerjahn F; Shinohara Y; Furukawa J; Petry F; Verbeek JS; Nishimura S; Ravetch JV; Izui S
J Immunol; 2008 Sep; 181(6):4107-12. PubMed ID: 18768867
[TBL] [Abstract][Full Text] [Related]
2. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice.
Baudino L; Nimmerjahn F; Azeredo da Silveira S; Martinez-Soria E; Saito T; Carroll M; Ravetch JV; Verbeek JS; Izui S
J Immunol; 2008 Feb; 180(3):1948-53. PubMed ID: 18209093
[TBL] [Abstract][Full Text] [Related]
3. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions.
Baudino L; Shinohara Y; Nimmerjahn F; Furukawa J; Nakata M; Martínez-Soria E; Petry F; Ravetch JV; Nishimura S; Izui S
J Immunol; 2008 Nov; 181(9):6664-9. PubMed ID: 18941257
[TBL] [Abstract][Full Text] [Related]
4. Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia.
Yamada K; Ito K; Furukawa J; Nakata J; Alvarez M; Verbeek JS; Shinohara Y; Izui S
J Autoimmun; 2013 Dec; 47():104-10. PubMed ID: 24055197
[TBL] [Abstract][Full Text] [Related]
5. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.
Fossati-Jimack L; Ioan-Facsinay A; Reininger L; Chicheportiche Y; Watanabe N; Saito T; Hofhuis FM; Gessner JE; Schiller C; Schmidt RE; Honjo T; Verbeek JS; Izui S
J Exp Med; 2000 Apr; 191(8):1293-302. PubMed ID: 10770797
[TBL] [Abstract][Full Text] [Related]
6. Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a.
Syed SN; Konrad S; Wiege K; Nieswandt B; Nimmerjahn F; Schmidt RE; Gessner JE
Eur J Immunol; 2009 Dec; 39(12):3343-56. PubMed ID: 19795417
[TBL] [Abstract][Full Text] [Related]
7. FcgammaRIV: a novel FcR with distinct IgG subclass specificity.
Nimmerjahn F; Bruhns P; Horiuchi K; Ravetch JV
Immunity; 2005 Jul; 23(1):41-51. PubMed ID: 16039578
[TBL] [Abstract][Full Text] [Related]
8. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
9. Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors.
Ding JW; Zhou T; Zeng H; Ma L; Verbeek JS; Yin D; Shen J; Chong AS
J Immunol; 2008 Jan; 180(1):261-8. PubMed ID: 18097027
[TBL] [Abstract][Full Text] [Related]
10. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
11. Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies.
Giorgini A; Brown HJ; Lock HR; Nimmerjahn F; Ravetch JV; Verbeek JS; Sacks SH; Robson MG
J Immunol; 2008 Dec; 181(12):8745-52. PubMed ID: 19050295
[TBL] [Abstract][Full Text] [Related]
12. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies.
Baudino L; Azeredo da Silveira S; Nakata M; Izui S
Springer Semin Immunopathol; 2006 Oct; 28(2):175-84. PubMed ID: 16953439
[TBL] [Abstract][Full Text] [Related]
14. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.
Azeredo da Silveira S; Kikuchi S; Fossati-Jimack L; Moll T; Saito T; Verbeek JS; Botto M; Walport MJ; Carroll M; Izui S
J Exp Med; 2002 Mar; 195(6):665-72. PubMed ID: 11901193
[TBL] [Abstract][Full Text] [Related]
15. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
16. In vitro functional characterization of feline IgGs.
Strietzel CJ; Bergeron LM; Oliphant T; Mutchler VT; Choromanski LJ; Bainbridge G
Vet Immunol Immunopathol; 2014 Apr; 158(3-4):214-23. PubMed ID: 24560097
[TBL] [Abstract][Full Text] [Related]
17. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.
Nimmerjahn F; Lux A; Albert H; Woigk M; Lehmann C; Dudziak D; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19396-401. PubMed ID: 20974962
[TBL] [Abstract][Full Text] [Related]
18. Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function.
Brinkhaus M; Douwes RGJ; Bentlage AEH; Temming AR; de Taeye SW; Tammes Buirs M; Gerritsen J; Mok JY; Brasser G; Ligthart PC; van Esch WJE; Verheesen P; de Haard H; Rispens T; Vidarsson G
J Immunol; 2020 Dec; 205(12):3456-3467. PubMed ID: 33188070
[TBL] [Abstract][Full Text] [Related]
19. Fc
Qiu A; Miller A; Zotti FD; Santhanakrishnan M; Hendrickson JE; Tredicine M; Stowell SR; Luckey CJ; Zimring JC; Hudson KE
Front Immunol; 2022; 13():972723. PubMed ID: 36189253
[TBL] [Abstract][Full Text] [Related]
20. IgG subclasses determine pathways of anaphylaxis in mice.
Beutier H; Gillis CM; Iannascoli B; Godon O; England P; Sibilano R; Reber LL; Galli SJ; Cragg MS; Van Rooijen N; Mancardi DA; Bruhns P; Jönsson F
J Allergy Clin Immunol; 2017 Jan; 139(1):269-280.e7. PubMed ID: 27246523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
